Page last updated: 2024-10-30

lofepramine and Parkinson Disease

lofepramine has been researched along with Parkinson Disease in 1 studies

Lofepramine: A psychotropic IMIPRAMINE derivative that acts as a tricyclic antidepressant and possesses few anticholinergic properties. It is metabolized to DESIPRAMINE.

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Howard, LM1
Markus, H1

Other Studies

1 other study available for lofepramine and Parkinson Disease

ArticleYear
Pseudo-obstruction secondary to anticholinergic drugs in Parkinson's disease.
    Postgraduate medical journal, 1992, Volume: 68, Issue:795

    Topics: Humans; Intestinal Pseudo-Obstruction; Lofepramine; Male; Mandelic Acids; Middle Aged; Parasympathol

1992